Full Press Release Details
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint.
BIIB
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Key Takeaway: Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis